BioSpace News Archive

Cellectis announced today the issuance of two U.S. patents - US 9,855,297 and US 9,890,393 - for the invention of certain uses of RNA-guided endonucleases, such as Cas9 or Cpf1, for the genetic engineering of T-cells.

A presentation of the results by the Company’s senior management team will take place today at 10.00 am CET in Oslo - details below.

A new study appearing in STEM CELLS Translational Medicine shows how understanding the way a type of molecule called CD133 functions might contribute to an understanding of the mechanisms involved in kidney repair.

Net revenue SEK 439.0 million

Chi-Med has completed patient enrollment of FALUCA, its Phase III pivotal trial of fruquintinib in advanced, third-line, non-small cell lung cancer (“NSCLC”) patients in China.

The revised study design is considered to optimize the treatment effect of Foxy-5, but will delay the study initiation compared to the previous estimate.

Both Oracle Argus cloud and on-premise deployments have been tested and are fully compliant with the new EV system.

Additionally, the Company is proactively looking for investment opportunities, if there are no suitable investment projects, the Board may consider declaring further special dividend.

Librede has been awarded a $1,490,000 Phase II Small Business Innovative Research Grant (SBIR) from the National Center for Complementary and Integrative Health (NCCIH), part of the National Institutes of Health (NIH), to further develop and scale their proprietary yeast-based cannabinoid production platform.

In 2007, highly-respected TMF thought leader Karen Roy joined Phlexglobal as Chief Business Development Officer and since 2015 has led Phlexglobal’s global Client Solutions team.